Cargando…

PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Munshi, N., Spencer, A., Raab, M. S., Masood, A., Martinez-Prieto, M., Chu, J., Iida, S., Lonial, S., Dimopoulos, M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429434/ http://dx.doi.org/10.1097/01.HS9.0000850768.54900.41

Ejemplares similares

PB2000: LESSONS LEARNED FROM CERBA RESEARCH CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) MULTIPLE MYELOMA RUNNING TRIALS
por: Gaspo, R., et al.
Publicado: (2022)

PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Mohammed, Turab, et al.
Publicado: (2023)

PB1999: ATG-010 PLUS LOW-DOSE DEXAMETHASONE (SD) IN CHINESE RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS PREVIOUSLY RECEIVED CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T)
por: Fu, W., et al.
Publicado: (2022)

PB2104: SOLUBLE B-CELL MATURATION ANTIGEN AS A MONITORING MARKER FOR MULTIPLE MYELOMA
por: Wiedemann, Ádám, et al.
Publicado: (2023)

PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
por: Accorsi Buttini, E., et al.
Publicado: (2022)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lonial, Sagar, et al.
Publicado: (2023)

PB1976: CRISPR-CAS9 KNOCKOUT SCREEN IDENTIFIES RNA MODIFICATION ENZYMES ESSENTIAL FOR CELL SURVIVAL IN MULTIPLE MYELOMA
por: Zhao, D., et al.
Publicado: (2022)

PB1969: FUNCTIONAL CHARACTERIZATION OF SUSCEPTIBILITY LOCI TO MULTIPLE MYELOMA
por: Shokouhi, M., et al.
Publicado: (2022)

PB1983: RELATIONSHIP BETWEEN REGULAR MOLECULAR MONITORING AND TREATMENT OUTCOMES IN CML PATIENTS IN ARMENIA
por: Harutyunyan, Lusine, et al.
Publicado: (2023)

PB1843: DONOR-DERIVED CLL-1 CHIMERIC ANTIGEN RECEPTOR T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BRIDGING TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT
por: Miao, Xiaojuan, et al.
Publicado: (2023)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

PB1916: DETECTION OF AUTOANTIBODIES TO NEUTROPHIL AND ERYTHROCYTE ANTIGENS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISEASES
por: Irina, Krobinets, et al.
Publicado: (2023)

PB1990: MULTIPLE MYELOMA IN THE ELDERLY: A MONOCENTRIC EXPERIENCE
por: Charfi, H., et al.
Publicado: (2022)

PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA
por: Vlachová, M., et al.
Publicado: (2022)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

PB1957: CIRCULATING MIRNA-16 AND MIRNA -21 EXPRESSION LEVELS IN MYELOMA; PRELIMINARY RESULTS.
por: Gkioka, A.-I., et al.
Publicado: (2022)

PB1791: ON THE ISSUE OF HOUSEKEEPING GENE PRIMER DESIGN FOR ADEQUATE ASSESSMENT OF THE EXPRESSION OF THE CHIMERIC TRANSCRIPTS.
por: Fevraleva, I., et al.
Publicado: (2022)

PB2015: YOUNG ADULTS WITH MULTIPLE MYELOMA – A SINGLE CENTER EXPERIENCE
por: Dos Santos Marques, I., et al.
Publicado: (2022)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
por: Semenova, N. Y., et al.
Publicado: (2022)

PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Delimpasi, S., et al.
Publicado: (2022)

PB2318: ACQUIRED WILLEBRAND SYNDROME REVEALING ASYMPTOMATIC MULTIPLE MYELOMA: A CASE REPORT
por: Chawad, W., et al.
Publicado: (2022)

PB1955: THE AGENDA FOR FUTURE MULTIPLE MYELOMA RESEARCH ACCORDING TO PATIENTS, CAREGIVERS, AND CLINICIANS
por: Fowler, S., et al.
Publicado: (2022)

PB1954: COMPARING STR PROFILES OF DNA ISOLATED FROM DIVERSE TUMOR SITES IN MULTIPLE MYELOMA
por: Firsova, M., et al.
Publicado: (2022)

PB2278: INVESTIGATION ON THE STATUS OF INFECTION IN PATIENTS WITH MULTIPLE MYELOMA
por: Lan, D., et al.
Publicado: (2022)

PB1975: THE RESEARCH ON THE MECHANISM OF RRAD GENE IN MULTIPLE MYELOMA
por: Yi, C., et al.
Publicado: (2022)

PB1981: EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA
por: Bougherira, S., et al.
Publicado: (2022)

PB1977: SPECTRUM OF INFECTIOUS COMPLICATIONS FOLLOWING TRANSPLANTATION OF AUTOLOGOUS BLOOD STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Abakumova, A., et al.
Publicado: (2022)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022)

PB2319: ACQUIRED COAGULOPATHY: FACTOR X DEFICIENCY AT DIAGNOSIS OF MULTIPLE MYELOMA WITHOUT ASSOCIATED AMYLOIDOSIS
por: De La Torre De La Paz, M., et al.
Publicado: (2022)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
por: Crusoe, E., et al.
Publicado: (2022)

PB2029: MULTIPLE MYELOMA AND SPINAL CORD COMPRESSION: THE EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Kallel, F., et al.
Publicado: (2022)

PB2012: A PHASE 2 MULTIARM STUDY OF MAGROLIMAB COMBINATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Paul, B., et al.
Publicado: (2022)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

PB1968: EPIGENETIC AND GENETIC INVESTIGATION OF SOCS-1 GENE IN PATIENTS WITH MULTIPLE MYELOMA
por: Serin, I., et al.
Publicado: (2022)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

PB2086: SIMULTANEOUS DIAGNOSIS OF MULTIPLE MYELOMA AND MYELODYSPLASIA: CASE REPORT.
por: Benabed, Khaled, et al.
Publicado: (2023)

PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS
por: Gkioka, Annita-Ioanna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lbp9sqle0flaebd3v09crnajh6